Pfizer news
The WiseView Research desk's stories that name Pfizer, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The PFE page →
- HeadlinePfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
- HeadlinePfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
- HeadlinePfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
- HeadlinePfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
- HeadlinePfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
- HeadlinePfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem
- HeadlineBristol Myers Squibb vs. Pfizer: Consistency vs.
- HeadlinePfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares
- HeadlinePfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
- HeadlinePfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
- HeadlinePfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
- HeadlinePfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow
- HeadlinePfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
- HeadlinePfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'
- HeadlinePfizer (PFE) Gains As Market Dips: What You Should Know
- HeadlinePfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
- HeadlineJohnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff
- HeadlinePfizer: The Earnings Test That Matters
- HeadlineEnodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
- HeadlinePfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?
- CongressRo Khanna sold $15,001 - $50,000 of PFE
- CongressRo Khanna bought $1,001 - $15,000 of PFE
- CongressRo Khanna bought $1,001 - $15,000 of PFE
- HeadlinePfizer's Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
- HeadlineInvestors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
- HeadlinePfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)
- HeadlinePfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results
- HeadlineWill Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
- HeadlineFDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
- HeadlinePfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not
- HeadlinePfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
- HeadlinePfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
- HeadlinePfizer to cut around 330 jobs in Italy
- HeadlineAstellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
- HeadlinePFE vs. JNJ: Which Stock Is the Better Value Option?
- HeadlineAre Investors Undervaluing Pfizer (PFE) Right Now?
- HeadlinePfizer Declares Fourth-Quarter 2026 Dividend
- HeadlinePfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
- HeadlinePfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
- HeadlineBetter High-Yield Dividend Stock: Pfizer or Novo Nordisk?
- HeadlinePfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
- HeadlinePfizer (PFE) Stock Sinks As Market Gains: What You Should Know
- HeadlinePfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
- HeadlineNovo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
- HeadlineNurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
- HeadlinePfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
- CongressRo Khanna bought $1,001 - $15,000 of PFE
- CongressMichael Rulli sold $1,001 - $15,000 of PFE
- CongressTommy Tuberville sold $15,001 - $50,000 of PFE
- CongressRo Khanna bought $1,001 - $15,000 of PFE
- CongressGilbert Cisneros bought $1,001 - $15,000 of PFE
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.